Ignite Creation Date:
2024-05-06 @ 3:46 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04747912
Status:
RECRUITING
Last Update Posted:
2023-08-25
First Post:
2021-02-05
Brief Title:
Study of Chemotherapy-Free Induction Regimen for Ph Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin InO
Sponsor:
University of Chicago
Organization:
University of Chicago
Study Overview
Official Title:
A Phase II Study of a Chemotherapy-Free Induction Regimen for Ph Acute Lymphoblastic Leukemia ALL Incorporating Inotuzumab Ozogamicin InO
Status:
RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research study will add an anti-cancer drug called inotuzumab ozogamicin also known as InO to treatment for participants with newly diagnosed Philadelphia chromosome-positive Ph acute lymphoblastic leukemia ALL Doctors leading this study hope to learn if adding InO to standard induction treatment for Ph ALL will lead to quicker complete molecular remission where the disease is not detectable even with very sensitive testing techniques The purpose of this research is to gather information regarding the effectiveness of InO in newly-diagnosed Ph ALL patients that have not yet received treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None